Stockscreener 앱 받기
0.4502
2.13%
-0.0098
시간 외 거래:
.45
-0.0002
-0.04%
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
How resilient is Sangamo Therapeutics Inc. stock in market downturnsJuly 2025 WrapUp & Low Drawdown Trading Techniques - ulpravda.ru
Can Sangamo Therapeutics Inc. stock attract ESG capital inflows2025 Risk Factors & Verified Short-Term Trading Plans - ulpravda.ru
Is Sangamo Therapeutics Inc. stock a contrarian buyJuly 2025 Recap & Fast Moving Stock Trade Plans - ulpravda.ru
Is Sangamo Therapeutics Inc. stock attractive for retirement portfolios2026 world cup usa national team group stage playmakers transition play odds analysis insights - ulpravda.ru
Will Sangamo Therapeutics Inc. stock reach Wall Street targets2026 world cup usa national team final top scorers possession football expert forecast preview - ulpravda.ru
Sangamo rises after trial data for Fabry disease therapy - MSN
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Sangamo Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Revenue Check: Will Sangamo Therapeutics Inc. (GBY) stock benefit from infrastructure bill2025 Big Picture & Detailed Earnings Play Strategies - Улправда
Why Sangamo Therapeutics Inc. stock could outperform in 2025Oil Prices & High Return Trade Guides - Улправда
Revenue Check: Can Sangamo Therapeutics Inc. stock surprise with earnings upsideJobs Report & Expert Approved Momentum Ideas - moha.gov.vn
Sangamo Starts Putting BLA for Fabry Disease Gene Therapy Isa-Vec in Front of FDA - CGTLive®
Growth Value: How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 PostEarnings & High Conviction Buy Zone Alerts - Улправда
How Sangamo Therapeutics Inc. stock trades before earningsJuly 2025 Gainers & Weekly Consistent Profit Watchlists - Улправда
Sangamo initiates rolling BLA submission for Fabry disease gene therapy By Investing.com - Investing.com Nigeria
Sangamo Therapeutics initiates rolling submission of BLA to U.S. FDA - marketscreener.com
Sangamo (SGMO) Begins BLA Submission for Promising Fabry Disease Therapy - GuruFocus
Sangamo initiates rolling BLA submission for Fabry disease gene therapy - Investing.com India
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - The Manila Times
Single-dose gene therapy for rare Fabry disease moves toward FDA review - Stock Titan
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Hold" by Analysts - MarketBeat
Sangamo Therapeutics Earnings Notes - Trefis
Sangamo reports positive Fabry disease gene therapy results - MSN
How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals - Yahoo Finance
Book value per share of Sangamo Therapeutics, Inc. – SWB:GBY - TradingView — Track All Markets
Inflation Data: Is Sangamo Therapeutics Inc stock positioned well for digital economy2025 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - moha.gov.vn
Sangamo receives U.S. FDA Fast Track Designation to ST-503 - MSN
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathyLife Science Industry News - Zenopa
Is Sangamo Therapeutics Stock Built to Withstand a Pullback? - Trefis
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - MSN
Why analysts recommend Sangamo Therapeutics Inc. (GBY) stockQuarterly Earnings Summary & Precise Buy Zone Identification - Newser
Will Sangamo Therapeutics Inc. (GBY) stock maintain strong growthBreakout Watch & Real-Time Buy Signal Alerts - Newser
Sangamo Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript - GuruFocus
Can Sangamo Therapeutics Inc. (GBY) stock attract analyst upgrades2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - Newser
Can Sangamo Therapeutics Inc. (GBY) stock reach $200 price targetPortfolio Gains Report & Low Risk High Win Rate Stock Picks - Newser
How reliable is Sangamo Therapeutics Inc. (GBY) stock dividend growth2025 Momentum Check & Expert Curated Trade Setup Alerts - Newser
How Sangamo Therapeutics Inc. (GBY) stock reacts to fiscal policiesQuarterly Trade Review & Capital Efficient Trading Techniques - Newser
Fabry treatment ST-920 boosts kidney, heart function in trial - Fabry Disease News
Sangamo's hemophilia A gene therapy revenue forecasts cut after Pfizer exit - S&P Global
SGMO SEC FilingsSangamo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
FDA grants fast track designation for Sangamo’s pain treatment By Investing.com - Investing.com Canada
How Sangamo Therapeutics Inc. (GBY) stock performs in volatility spikesMarket Growth Report & Expert Approved Momentum Trade Ideas - Newser
Sangamo Therapeutics (SGMO) Stock: Gains FDA Fast Track for ST-503 in SFN Pain Treatment - parameter.io
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 29% Price Drop - 富途牛牛
Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - marketscreener.com
Sangamo Therapeutics (SGMO) Surges on FDA Fast Track Designation for ST-503 - GuruFocus
Sangamo (SGMO) Gains FDA Fast Track for Chronic Pain Treatment - GuruFocus
Sangamo Therapeutics secures FDA fast track for ST-503 - Traders Union
Sangamo Therapeutics receives U.S. FDA fast track designation for ST-503 - marketscreener.com
Sangamo Therapeutics (Nasdaq: SGMO) gets FDA Fast Track for ST-503 in small fiber neuropathy - Stock Titan
Sangamo Therapeutics (SGMO) Stock Analysis Report | Financials & Insights - Benzinga
0.80%
4.56%
자본화:
|
볼륨(24시간):